BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 127553
Published online Nov 24, 2026. doi: 10.5306/wjco.127553
Association of one-year postoperative patient-reported outcomes with recurrence and survival in stage I non-small-cell lung cancer
Giovanni Leuzzi, Beatrice Cosentino, Federica Sabia, Ugo Pastorino, Cecilia Pompili, Wei Dai, Francesco Guerrera, Elena Prisciandaro, Filippo Lococo, Michele Ferrari, Luigi Rolli, Alessandro Pardolesi, Alessia Stanzi, Matteo Calderoni, Clarissa Uslenghi, Daniele Lorenzini, Alessandra Fabbri, Claudia Proto, Giuseppe Lo Russo, Arsela Prelaj, Alfonso Marchianò, Giorgio Greco, Piergiorgio Solli
Giovanni Leuzzi, Beatrice Cosentino, Federica Sabia, Michele Ferrari, Luigi Rolli, Alessandro Pardolesi, Alessia Stanzi, Matteo Calderoni, Clarissa Uslenghi, Piergiorgio Solli, Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Ugo Pastorino, Lung Cancer Prevention Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Cecilia Pompili, Department of Thoracic Surgery, Institute for Clinical & Applied Health Research, University of Hull, Hull HU6 7RX, United Kingdom
Wei Dai, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu 610041, Sichuan Province, China
Francesco Guerrera, Department of Cardio-Thoracic and Vascular Surgery, Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Turin 10126, Piedmont, Italy
Elena Prisciandaro, Department of Thoracic Surgery, Hôpitaux Universitaires de Bruxelles, Bruxelles 1070, Belgium
Filippo Lococo, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome 00168, Italy
Daniele Lorenzini, Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Alessandra Fabbri, The 2nd Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Claudia Proto, Giuseppe Lo Russo, Arsela Prelaj, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Alfonso Marchianò, Giorgio Greco, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Lombardy, Italy
Co-first authors: Giovanni Leuzzi and Beatrice Cosentino.
Author contributions: Leuzzi G and Cosentino B contributed to the conception and design of the study as co-first authors; Leuzzi G, Pastorino U, Sabia F, Ferrari M, Rolli L, Pardolesi A, Stanzi A, Calderoni M, and Uslenghi C contributed to the collection and assembly of data; Cosentino B performed the data analysis; and all authors contributed to data interpretation; Leuzzi G and Cosentino B drafted the manuscript; and all authors critically revised the manuscript and approved the final version.
AI contribution statement: OpenAI ChatGPT was used solely for language revision. All changes were reviewed and approved by the authors.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Protocol No. INT 6-25; approval date: February 7, 2025).
Informed consent statement: In accordance with the Italian Privacy Code (D.Lgs. 196/2003, Art. 110-bis, par. 4) and the retrospective design of the study, the Institutional Review Board approved the use of existing de-identified data and waived the requirement for individual re-consent.
Conflict-of-interest statement: The authors declare no conflicts of interest related to this work.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: The data underlying this article will be shared on reasonable request to the corresponding author, subject to institutional approval and applicable privacy regulations.
Corresponding author: Giovanni Leuzzi, MD, Consultant, Senior Researcher, Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, Milan 20133, Lombardy, Italy. giovanni.leuzzi@istitutotumori.mi.it
Received: September 1, 2026
Revised: September 20, 2026
Accepted: October 28, 2026
Published online: November 24, 2026
Processing time: 77 Days and 7.3 Hours
Abstract
BACKGROUND

Recurrence risk and overall survival (OS) after curative-intent resection for stage I non-small-cell lung cancer remain incompletely explained by tumor-related variables. Patient-reported outcomes may capture dimensions of postoperative health not represented by conventional clinicopathologic factors, but their prognostic role during survivorship remains insufficiently defined.

AIM

To determine whether patient-reported outcomes assessed 1 year after surgery are associated with subsequent recurrence and OS.

METHODS

We analyzed 349 consecutive patients undergoing resection for pathological stage I non-small-cell lung cancer (NSCLC) between 2006 and 2018. The 1-year landmark cohort comprised 232 patients alive and recurrence-free with available health-related quality of life data. Global health status (QL2), fatigue (FA), and dyspnea (DY) from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 were evaluated. Recurrence was the primary endpoint, with death treated as a competing event. Multivariable recurrence analyses used cause-specific Firth Cox and Fine-Gray models; OS was assessed using multivariable Firth Cox regression.

RESULTS

During follow-up, 35 patients (15.1%) developed recurrence and 15 (6.5%) died without prior relapse. Age ≥ 65 years [hazard ratio (HR) = 6.51, 95%CI: 2.37-17.90], higher QL2 (HR = 2.50, 95%CI: 1.15-5.40), and higher FA (HR = 3.48, 95%CI: 1.66-7.27) were independently associated with recurrence, whereas DY was inversely associated (HR = 0.33, 95%CI: 0.16-0.71). Fine-Gray models yielded consistent estimates. For OS, age ≥ 65 years (HR = 4.90, 95%CI: 1.19-20.05) and DY > 0 (HR = 0.26, 95%CI: 0.09-0.81) were independently associated with mortality, whereas FA ≥ 22.2 showed a clinically relevant but borderline association (HR = 2.94, 95%CI: 0.96-9.02). Model discrimination was good for recurrence (C-index 0.79) and OS (C-index 0.73).

CONCLUSION

Postoperative patient-reported outcomes assessed at 1 year were associated with heterogeneous recurrence and survival trajectories, suggesting complementary prognostic information during survivorship after stage I NSCLC resection.

Keywords: Non-small-cell lung cancer; Patient-reported outcomes; Health-related quality of life; Recurrence; Overall survival; Survivorship

Core Tip: This landmark study evaluated whether patient-reported outcomes assessed 1 year after curative-intent resection for stage I non-small-cell lung cancer were associated with subsequent recurrence and survival. Among 232 patients alive and recurrence-free at the landmark, global health status, fatigue, and dyspnea showed distinct associations with recurrence, while dyspnea was associated with overall survival and fatigue showed a borderline association in the primary model. These findings suggest that postoperative patient-reported outcomes may provide complementary prognostic information during long-term survivorship.

Write to the Help Desk